Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $1.6 million.

  • CytomX Therapeutics' Interest & Investment Income fell 596.57% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 4016.27%. This contributed to the annual value of $7.1 million for FY2024, which is 2745.76% down from last year.
  • CytomX Therapeutics' Interest & Investment Income amounted to $1.6 million in Q3 2025, which was down 596.57% from $1.2 million recorded in Q2 2025.
  • CytomX Therapeutics' Interest & Investment Income's 5-year high stood at $2.7 million during Q3 2023, with a 5-year trough of $44000.0 in Q2 2021.
  • Moreover, its 5-year median value for Interest & Investment Income was $1.2 million (2025), whereas its average is $1.2 million.
  • As far as peak fluctuations go, CytomX Therapeutics' Interest & Investment Income crashed by 9367.44% in 2021, and later soared by 332205.88% in 2023.
  • CytomX Therapeutics' Interest & Investment Income (Quarter) stood at $73000.0 in 2021, then surged by 902.74% to $732000.0 in 2022, then skyrocketed by 241.94% to $2.5 million in 2023, then crashed by 48.94% to $1.3 million in 2024, then rose by 24.57% to $1.6 million in 2025.
  • Its Interest & Investment Income was $1.6 million in Q3 2025, compared to $1.2 million in Q2 2025 and $955000.0 in Q1 2025.